Year: 2021

Studying the Role of BRCA1 in Regulating Heterochromatin Structure and Function in Ovarian Cancer

Project summary coming…

Read on

Genome-Wide Profiling of 5-hydroxymethylcytosine on Cell-Free DNA

Ovarian cancer (OvCa) is the fifth most common cause of cancer related deaths among women in the United States with estimates predicting that in 2020 about 21,750 women will be diagnosed with the disease…

Read on

Targeted MDM2 Degradation as a Novel Treatment for Ovarian Cancer

High grade serous ovarian cancer (HGSOC) is the most prevalent subtype of ovarian cancer. It is aggressive and has a poor overall survival rate…

Read on

APOBEC3B and DNA Repair as Synthetic Lethal Combinations in CCOC

Clear Cell Ovarian Carcinoma (CCOC) is one of the most clinically challenging types of ovarian cancer. The current standard-of-care consists in surgical resection and platinum therapy…

Read on

Spatially-Resolved Cellular and Transcriptome Analyses of Ovarian Cancer

More than 14,000 patients in the United States die of ovarian cancer each year, making this cancer the fifth leading cause of cancer death among women in the United States…

Read on

Role of Ribosomal Protein Mono(ADP-ribosyl)ation in Protein Quality Control

Fast dividing cells such as cancer cells require high levels of protein synthesis to support cell growth. But when protein synthesis is too high, the proteins cannot be folded accurately resulting in the accumulation of toxic protein aggregates…

Read on

Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM

The DNA double helix, which stores our genetic information, is constantly damaged by various agents such as reactive chemicals or even sunlight, but our cells are equipped with machineries made up of proteins that repair damages to DNA…

Read on

Determine Resistance Mechanisms to ATR Inhibition in Ovarian Cancers

Ovarian cancer remains the most fatal gynecological cancer. The major cause for continuous low survival rates is the challenge of early detection…

Read on

A Novel Mechanism for the Immunomodulatory Effects of PARP-inhibitor

Poly (ADP-ribose) polymerase (PARP)-inhibitors are an emerging class of medicines for women with recurrent ovarian cancer and improving patients’ prognosis…

Read on

Exploiting a Metabolic Dependency of PARPinhibitor-Resistant Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) remains the deadliest form of ovarian cancer, in part because most patients develop recurrent disease that is resistant to standard treatment, including platinum therapy…

Read on

Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) accounts for more than 70% of all ovarian cancer deaths. Most women with HGSOC are diagnosed when the disease is at an advanced, and therefore less curable, stage…

Read on

EGFL6 as a New Regulator of Myeloid Cell Expansion and Function in HGSOC

Ovarian cancer (OvCa) is the deadliest US gynecologic malignancy with a clear need for novel therapeutic approaches…

Read on